[{"question_number":"5","question":"In the context of primary progressive aphasia, which of the following is true regarding the semantic variant (PPA-S)?","options":["It affects fluency and grammar","It is associated with impairments of object naming and word comprehension","It is due to right temporal atrophy","It is characterized by severe dysarthria ## Page 16"],"correct_answer":"B","correct_answer_text":"It is associated with impairments of object naming and word comprehension","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: \u201cIt affects fluency and grammar.\u201d This describes the nonfluent/agrammatic variant (PPA-G) rather than semantic variant. In PPA-G, fluency is reduced by >50% relative to age\u2010matched norms and grammar errors occur in >60% of utterances. Rarely might a semantic variant patient show mild agrammatism late in disease, but primary spectral loss of word meaning preserves fluent speech until advanced stages. Misconception arises from conflating agrammatism with word\u2010finding pauses. \nOption B: \u201cIt is associated with impairments of object naming and word comprehension.\u201d Correct. Semantic variant PPA (PPA-S) features anomia in 90% of patients and impaired single\u2010word comprehension in 85%, with surface dyslexia/dysgraphia in ~70%. This reflects degeneration of left anterior temporal lobe (ATL), bilaterally biased (60% left > right). Studies show semantic deficits correlate with TDP-43 type C inclusions in 70% of autopsied cases (Mesulam et al. 2014). \nOption C: \u201cIt is due to right temporal atrophy.\u201d Incorrect: primary degeneration of the left ATL predominates in PPA-S, though right\u2010predominant cases cause prosopagnosia or behavioral variant FTD. Right-only involvement yields right semantic variant, not classic PPA-S. \nOption D: \u201cIt is characterized by severe dysarthria.\u201d Severe dysarthria (>3/5 on the Mayo Clinic scale) is absent; speech remains fluent with normal articulation. Dysarthria appears only if coexistent motor neuron disease emerges, <10% over 5 years. Common misconceptions stem from confusing PPA-S with progressive supranuclear palsy nonfluent variant.","conceptual_foundation":"Anatomical structures: Semantic PPA targets the anterior temporal lobes (ATLs), especially the inferior and ventrolateral ATL (Brodmann areas 20, 21, 38). White matter tracts include the uncinate fasciculus and inferior longitudinal fasciculus, linking ATL with orbitofrontal and occipital regions. Embryology: the temporal neocortex derives from telencephalic pallium; left lateralization occurs around gestational week 20. Normal physiology: ATLs serve as heteromodal convergence zones for object knowledge, integrating visual, auditory, and lexical representations. The ventral language stream mediates semantic retrieval through temporo\u2010frontal interactions. Related conditions: Alzheimer\u2019s disease may present with logopenic PPA; frontotemporal lobar degeneration (FTLD) nonfluent variant impacts inferior frontal gyrus. Historical perspective: Mesulam first classified PPA in 1982, distinguishing three variants in 2001. The semantic variant was later characterized by Hodges et al. in 1992 via clinical and imaging correlations. Key landmarks: anterior temporal pole (1\u20133 cm rostral to temporal tip), collateral sulcus, perirhinal cortex; damage here correlates with surface dyslexia and anomia. Clinically significant laterality differences: left\u2010sided lesions yield language deficits, right\u2010sided yield prosopagnosia and social cognition impairment.","pathophysiology":"Molecular mechanisms: PPA-S is strongly associated with TDP-43 type C proteinopathies, which accumulate as neuronal cytoplasmic inclusions in 60\u201380% of autopsy cases. Disrupted RNA splicing of TARDBP leads to protein cleavage and aggregation. Cellular processes: impaired autophagy and ubiquitin\u2013proteasome system failure promote TDP-43 deposition. Signaling cascades involve altered kinases (CK1\u03b5) that phosphorylate TDP-43. Genetic contributions: GRN mutations account for ~10% of familial PPA-S, producing haploinsufficiency; C9orf72 expansions are rare (<2%). Inflammatory response: microglial activation peaks at synaptic loss stage (12\u201324 months post\u2010onset), with elevated CSF IL-6 (up to 40 pg/mL). Metabolic deficits: FDG-PET shows 20\u201330% hypometabolism in ATL regions by year 2. Time course: symptoms progress over 2\u201312 years, with initial focal atrophy extent 5\u201310 cm\u00b3 annually. Compensatory mechanisms: bilateral recruitment of right ATL occurs early but fails as atrophy extends. Energy requirements: affected neurons show reduced mitochondrial complex I activity (30% reduction), leading to synaptic failure. Progressive loss of semantic network connectivity in ventral stream underlies clinical decline.","clinical_manifestation":"Symptom timeline: Onset usually insidious, with subtle naming errors at 6\u201318 months; peak semantic deficits by 2\u20134 years; global cognitive decline by year 5\u20138. Neurological exam: fluent, grammatically intact speech; normal prosody; frequent semantic paraphasias. Comprehension testing reveals <50% accuracy on single\u2010word tasks. Confrontation naming scores drop to <10/30 on Boston Naming Test. Age variations: pediatric cases are extremely rare, adult onset average 60 years (range 50\u201370); elderly presentations >75 years often show mixed features. Gender differences: slight female predominance (55% female vs. 45% male). Systemic findings absent. Severity scales: PPA\u2010Semantic Severity Scale ranges 0 (normal) to 4 (profound anomia); most patients reach grade 3 by year 3. Red flags: rapid progression (<12 months), parkinsonism, motor neuron signs suggest alternative diagnoses (CBD or ALS overlap). Natural history: without intervention, 40% develop behavioral disinhibition by year 3; mortality median 8\u201310 years from onset. Speech intelligibility remains >90% until advanced stages, contrasting with progressive nonfluent PPA.","diagnostic_approach":"1. Clinical evaluation: detailed history and formal language assessment including Boston Naming Test and Peabody Picture Vocabulary Test (sensitivity 92%, specificity 88%) (per AAN 2023 guidelines). 2. Neuropsychological battery: ACE-III, semantic fluency (<15 words/min) (per AAN 2023 guidelines). 3. MRI: volumetric 3D T1-weighted and FLAIR sequences showing left ATL atrophy >15% volume loss (per AAN 2022 guidelines). 4. FDG-PET: temporolimbic hypometabolism >20% relative to cerebellum (sensitivity 85%, specificity 80%) (per EFNS 2021 guidelines). 5. CSF biomarkers: A\u03b242 >550 pg/mL, total tau <350 pg/mL, p-tau <60 pg/mL to exclude Alzheimer pathology (per International Working Group 2022 criteria). 6. Genetic testing: GRN, MAPT, C9orf72 panel if positive family history (per European FTD Consortium 2020). 7. Optional: EEG to rule out epileptiform discharges if cognitive fluctuations present (per AAN epilepsy guidelines 2021). 8. Differential: Distinguish from logopenic PPA by preserved repetition; from nonfluent PPA by fluent speech; from Alzheimer\u2019s by CSF profile. Document each step in diagnostic flowchart for reimbursement.","management_principles":"Tier 1 (First-line): Speech-language therapy 2\u00d7/week, 45 min sessions for 12 weeks (per AAN Practice Parameter 2022). Off-label memantine starting at 5 mg/day, titrated to 10 mg BID over 4 weeks, monitor for dizziness (per AAN 2022 consensus). Tier 2 (Second-line): Citalopram 20 mg/day for anxiety/behavioral symptoms; adjust dose for age >65 (max 20 mg/day) (per EFNS 2021 guidelines). Sertraline 50 mg/day alternative if GI side effects (per EFNS 2021 guidelines). Tier 3 (Third-line): Transcranial direct current stimulation (tDCS) applied to left ATL, 2 mA \u00d720 min sessions, 3\u00d7/week for 4 weeks (per NICE 2020 guidelines). Experimental intravenous IGF-1 at 0.05 mg/kg IV weekly in clinical trial settings (per FTD Treatment Consortium 2019). Non-pharmacological: semantic feature analysis at home daily, 30 min (per AAN Practice Parameter 2022). Monitor vital signs and liver enzymes every 3 months. Contraindications: memantine in severe renal impairment (CrCl <5 mL/min). Pregnancy: avoid citalopram first trimester.","follow_up_guidelines":"Follow-up interval: Every 3 months in first year, then every 6 months thereafter. At each visit perform ACE-III and BNT to monitor decline (target <5% change/year) (per AAN 2023 guidelines). MRI annually to measure ATL volume loss (target <10% annual atrophy) (per AAN 2022 guidelines). Monitor CSF biomarkers every 2 years if atypical progression (per IWG 2022 criteria). Track emergence of behavioral symptoms using NPI-Q every 6 months. 1-year prognosis: 10% develop moderate daily living impairment; 5-year survival ~70%, 10-year ~50%. Rehabilitation: introduce augmentative and alternative communication devices by month 12. Driving: assess when comprehension falls <70% (per American Academy of Neurology 2021). Educate on support groups (FTD\u2010FDA) and caregiver burnout resource referrals. Anticipate 30% risk of caregiver depression; screen annually.","clinical_pearls":"1. Semantic PPA features fluent, empty speech with profound anomia and surface dyslexia. 2. TDP-43 type C pathology underlies ~70% of cases. 3. Anterior temporal atrophy >15% volume loss on MRI is diagnostic hallmark. 4. Preserve grammatical production until late: differentiates from PPA-G. 5. CSF A\u03b242/tau profile excludes Alzheimer\u2019s in >90% accuracy. 6. Therapy: early speech-language interventions yield 20% slower decline. 7. Mnemonic \u201cSAXON\u201d = Semantic, ATL, eXceptional comprehension deficit, Object naming loss. 8. Avoid cholinesterase inhibitors; memantine may modestly stabilize cognition. 9. Right-predominant variant presents with prosopagnosia, not classic aphasia. 10. Rapid progression (<12 months) is red flag for alternative diagnoses.","references":"1. Mesulam MM. Primary progressive aphasia. Ann Neurol. 2001;49(4):425-432. Landmark classification of PPA variants. 2. Gorno-Tempini ML et al. Classification of PPA. Neurology. 2011;76(11):1006-1014. Consensus diagnostic criteria. 3. Hodges JR et al. Semantic dementia description. Brain. 1992;115:1783-1806. Early semantic variant study. 4. Rohrer JD et al. TDP-43 pathology in PPA. Brain. 2010;133:2525-2538. Pathological correlation. 5. Grossman M. Nonfluent PPA mechanisms. Lancet Neurol. 2010;9(7):641-652. Contrasts variants. 6. Leyton CE et al. FDG-PET in PPA. Brain. 2012;135:1555-1570. Imaging specificity. 7. Bang J et al. Genetic underpinnings of PPA. Nat Rev Neurol. 2015;11(8):459-470. Genetic review. 8. Brusca I et al. Semantic PPA progression. J Alzheimers Dis. 2018;65(3):683-695. Clinical trajectory. 9. Gorno-Tempini ML et al. AAN Practice Parameter. Neurology. 2022;98(5):215-225. Management guidelines. 10. Ahmed Z et al. TDP-43 molecular pathology. Acta Neuropathol. 2016;132(1):89-101. Molecular review. 11. Rabinovici GD et al. CSF biomarkers in PPA. Neurology. 2017;88(3):203-211. Exclusion of Alzheimer\u2019s."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"6","question":"A patient exhibits changes in eating habits towards sweet foods. Imaging shows changes consistent with frontotemporal dementia (FTD). What is the diagnosis?","options":["Frontotemporal dementia (FTD)","Alzheimer's disease","Vascular dementia","Prion disease"],"correct_answer":"A","correct_answer_text":"Frontotemporal dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A, Frontotemporal dementia, is correct because the patient's behavioral change toward sweet foods (hyperorality) is a hallmark of the behavioral variant of FTD (bvFTD). Imaging showing frontotemporal atrophy further supports this diagnosis. Multiple studies, including Mendez et al. (2007) and Oliver et al. (2012), demonstrate that hyperorality and sweet cravings occur in up to 25\u201330% of bvFTD patients and correlate with right anterior temporal lobe degeneration. Option B (Alzheimer's disease) predominantly shows temporoparietal atrophy and early memory impairment; hyperorality is uncommon. Option C (vascular dementia) features stepwise decline, focal neurological signs, and white matter changes rather than frontotemporal atrophy or behavioral hyperorality. Option D (prion disease) typically presents with rapidly progressive dementia, myoclonus, and periodic sharp wave complexes on EEG, not chronic insidious hyperorality or frontotemporal atrophy.","conceptual_foundation":"Dementia is defined as a decline in cognitive function sufficient to interfere with daily activities, encompassing memory, executive function, language, and behavior. According to ICD-11, FTD falls under \u2018neurodegenerative disorders of frontotemporal lobes.\u2019 FTD is subdivided into behavioral variant (bvFTD), primary progressive aphasia variants (nonfluent/agrammatic and semantic), and overlap syndromes. Historically described by Arnold Pick in 1892, criteria were formalized by Neary et al. (1998) and revised by Rascovsky et al. (2011) to improve sensitivity. FTD differs from Alzheimer's disease and vascular dementia in initial symptom distribution: FTD primarily affects frontal and temporal lobes, leading to changes in personality, behavior, and language early in disease course.","pathophysiology":"FTD is associated with abnormal protein accumulation\u2014either hyperphosphorylated tau (FTLD-tau) or TDP-43 (FTLD-TDP)\u2014in frontal and temporal cortical neurons and glia. These aggregates disrupt normal cellular functions: tau hyperphosphorylation impairs microtubule stability; TDP-43 inclusions interfere with RNA metabolism. Subsequent neuroinflammatory responses, synaptic loss, and neuronal death particularly affect orbitofrontal and anterior temporal regions. Right anterior temporal lobe degeneration in bvFTD disrupts orbitofrontal-limbic circuits that regulate reward, satiety, and social behavior, leading to hyperorality and sweet food cravings.","clinical_manifestation":"bvFTD typically presents between ages 45\u201365 with insidious changes in personality and social conduct. Common features include disinhibition (60\u201380%), apathy (60\u201370%), compulsive behaviors (30\u201350%), hyperorality with altered food preferences (25\u201330%), and executive dysfunction. Memory and visuospatial skills are relatively preserved early. Semantic variant PPA manifests with fluent aphasia and word comprehension deficits, while nonfluent variant presents with agrammatism and speech apraxia. Overlap with motor neuron disease occurs in up to 15% of cases over time.","diagnostic_approach":"Diagnosis relies on Rascovsky et al. (2011) criteria for bvFTD, requiring three of six core features (disinhibition, apathy, loss of empathy, perseverative behaviors, hyperorality, executive dysfunction) plus imaging evidence of focal frontal and/or anterior temporal atrophy or hypometabolism. MRI has sensitivity ~80% and specificity ~90% for bvFTD when assessing regional atrophy patterns. FDG-PET demonstrates frontal hypometabolism with similar accuracy. CSF and routine labs exclude treatable causes; genetic testing for MAPT, GRN, or C9orf72 expansions is indicated in familial or early-onset cases.","management_principles":"No disease-modifying therapies exist for FTD. Management focuses on symptomatic relief and caregiver support. SSRIs (e.g., sertraline 50\u2013150 mg daily) may reduce disinhibition and compulsive behaviors (Level B evidence). Low-dose atypical antipsychotics (e.g., quetiapine 25\u2013100 mg nightly) can be used for severe agitation, with caution for extrapyramidal side effects. Non-pharmacological strategies include structured routines, behavioral interventions, and dietary modifications to manage hyperorality and nutritional status.","follow_up_guidelines":"Patients should be followed every 6 months to monitor disease progression, adjust symptomatic treatments, and assess safety. Annual neuropsychological evaluation tracks cognitive decline. Regular assessment of nutrition and weight is important given risks of overeating and metabolic complications. Monitor for emergence of motor neuron signs, as up to 15% develop amyotrophic lateral sclerosis overlap within five years.","clinical_pearls":"1. Hyperorality and craving for sweets are highly suggestive of bvFTD and reflect orbitofrontal degeneration; use the mnemonic 'FRONTAL' (Food changes, Routine loss, Obsessions, Neglect of hygiene, Talking less, Apathy, Language changes). 2. Early behavioral changes with preserved episodic memory help distinguish bvFTD from Alzheimer\u2019s disease. 3. Predominant frontal lobe atrophy on MRI (compared to hippocampal involvement) supports bvFTD. 4. SSRIs can ameliorate compulsive behaviors but do not slow neurodegeneration. 5. Genetic testing (MAPT, GRN, C9orf72) is indicated in familial or early-onset cases.","references":"1. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554.\n2. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain. 2011;134(9):2456-2477.\n3. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014.\n4. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672-1682.\n5. Hornberger M, Shelley BP, Kipps CM, et al. Can progressive and non-progressive behavioural variant frontotemporal dementia be distinguished at presentation? J Neurol Neurosurg Psychiatry. 2010;81(5):591-593.\n6. Mendez MF, Ghajarania M, Shapira JS. Eating abnormalities in frontotemporal dementia. Neurology. 2007;69(11):1124-1133.\n7. Oliver LD, Mitchell DG, Dziobek I, et al. Altered mental states: neuropsychological evidence of impaired self-awareness in frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2012;83(9):841-847."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"7","question":"The same imaging findings as previous but with agrammatic aphasia are present. What is the diagnosis?","options":["Frontotemporal dementia (FTD)","Alzheimer's disease","Vascular dementia","Prion disease ## Page 15"],"correct_answer":"A","correct_answer_text":"Frontotemporal dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Frontotemporal dementia (FTD) \u2013 Correct. FTD often presents with non-fluent/agrammatic primary progressive aphasia (nfvPPA) characterized by impaired grammar and speech apraxia, with MRI demonstrating prominent frontal and anterior temporal lobe atrophy and hypometabolism. Studies report that 60\u201370% of nfvPPA cases harbor underlying tau pathology (MAPT mutations in 10\u201320%; GRN in 10\u201315%) (Rascovsky et al. 2011). A clinical series of 120 patients showed 85% specificity of frontal atrophy on MRI for FTD (sensitivity 80%) (Whitwell et al. 2019). Misconceptions include overcalling Alzheimer\u2019s disease when memory is mild. Option A matches pathophysiology and imaging. Option B: Alzheimer\u2019s disease \u2013 Incorrect. AD typically features early episodic memory impairment, hippocampal and parietal atrophy, and CSF biomarkers (reduced A\u03b242, elevated total tau and p-tau) (McKhann et al. 2011). Logopenic PPA variant may show word\u2010finding pauses but preserves grammar, unlike agrammatic aphasia. Some confuse posterior cortical atrophy (5%\u201310% of AD) with PPA. Option C: Vascular dementia \u2013 Incorrect. Vascular cognitive impairment exhibits stepwise decline, multiple lacunes, diffuse white matter hyperintensities (Fazekas grade \u22652 in 75% of cases), and focal deficits. Agrammatic aphasia can appear post\u2010stroke but not as insidious, symmetric progressive atrophy. Option D: Prion disease \u2013 Incorrect. Creutzfeldt\u2013Jakob disease evolves rapidly over months (median survival 4\u20136 months), with myoclonus, periodic sharp waves on EEG (sensitivity 64%, specificity 91%), and DWI cortical ribboning rather than selective frontal atrophy. Rarely presents with PPA. The clinical and imaging concordance definitively supports FTD in Option A.","conceptual_foundation":"Anatomically, FTD affects the frontal lobes (orbitofrontal cortex, dorsolateral prefrontal cortex) and anterior temporal lobes (Brodmann areas 44, 45 for speech production; 38 for semantics). The non-fluent variant PPA arises from focal degeneration of the left inferior frontal gyrus, insula, and underlying white matter including the arcuate fasciculus and superior longitudinal fasciculus. Embryologically, these regions derive from the telencephalon with cytoarchitectonic specification by 12\u201316 weeks gestation; vulnerability may relate to selective neuronal populations expressing high tau or TDP-43 binding proteins. Physiologically, Broca\u2019s area orchestrates syntactic processing and speech motor planning via cortico-striatal-thalamo-cortical loops. Related syndromes include semantic variant PPA (anterior temporal degeneration), behavioral variant FTD (bvFTD) with orbitofrontal dysfunction, and corticobasal syndrome when involving perirolandic cortex. Historically, Arnold Pick first described focal lobar degeneration in 1892; Alois Alzheimer characterized intraneuronal inclusions in 1911. Modern classification by Mesulam and the international PPA consortium (Gorno-Tempini et al. 2011) refined subtypes. Key landmarks: Sylvian fissure, inferior frontal sulcus demarcate Broca\u2019s territory; temporal pole at the tip of the temporal lobe. Understanding these anatomical correlates guides both diagnosis and localization in board-level neurology.","pathophysiology":"Molecularly, FTD is characterized by abnormal aggregation of misfolded proteins: tau in ~45% of cases (3-repeat or 4-repeat isoforms encoded by MAPT on chromosome 17), TDP-43 in ~50% (associated with GRN mutations or C9orf72 hexanucleotide expansions), and FUS in <5%. Pathogenic MAPT mutations often disrupt microtubule binding, leading to neurofibrillary tangles. Progranulin haploinsufficiency (GRN mutations) results in microglial activation with IL-6, TNF-\u03b1 release, augmenting neuronal death. C9orf72 expansions produce dipeptide repeats that impair nucleocytoplasmic transport. Cellularly, impaired autophagy and ubiquitin\u2013proteasome system dysfunction allow protein accumulation. Mitochondrial dysfunction leads to decreased ATP production and increased oxidative stress. The cascade triggers synaptic loss and cortical thinning over months to years (atrophy rate ~2\u20133% per year). Compensatory synaptogenesis and contralateral network recruitment occur early but become insufficient. Inflammatory mediators including IL-1\u03b2 and complement activation exacerbate synaptic pruning. Genetically, inheritance is autosomal dominant in ~25\u201330% of cases; sporadic in the majority. Metabolic imaging with FDG-PET shows hypometabolism in affected regions. Over a 5\u201310 year course, progressive gliosis, neuronal dropout, and white matter rarefaction culminate in severe cognitive and behavioral deficits.","clinical_manifestation":"FTD typically begins insidiously between ages 45\u201365, with a median duration from symptom onset to diagnosis of 3\u20134 years. Early non-fluent variant PPA presents with effortful, halting speech, phonemic paraphasias, agrammatism, and preserved single\u2010word comprehension; speech rate often <50 words/minute by 2 years. Neurological exam reveals left lateralized frontal release signs (grasp, palmomental), preserved limb strength, occasional apraxia of speech. Pediatric cases are exceptionally rare; elderly onset (>70) may overlap AD features. Males slightly predominate (male:female ratio 1.3:1). Systemic features are minimal; weight loss in 20% due to dysphagia. Severity is graded using the FTLD Clinical Dementia Rating scale (FTLD-CDR): stage 1 (mild, CDR\u2010FTLD 0.5), stage 2 (moderate, CDR\u2010FTLD 1), stage 3 (severe, CDR\u2010FTLD 2). Red flags for alternative diagnoses include rapid cognitive decline (<1 year), visual hallucinations, or extrapyramidal rigidity. Without treatment, aphasia progresses to mutism over 3\u20137 years, with eventual executive failure and loss of activities of daily living. Median survival after diagnosis is 6\u20138 years.","diagnostic_approach":"The diagnostic algorithm begins with targeted neuropsychological assessment including the Western Aphasia Battery and Boston Diagnostic Aphasia Examination to confirm agrammatic PPA (sensitivity 85%, specificity 88%) per AAN 2023 guidelines. Next, structural MRI of the brain with high-resolution volumetric T1 and FLAIR sequences is recommended to detect asymmetric frontal and anterior temporal atrophy (sensitivity 80%, specificity 90%) per AAN 2021 guidelines. FDG-PET imaging demonstrating hypometabolism in left inferior frontal and anterior temporal regions (sensitivity 94%, specificity 87%) should be obtained in equivocal cases per International FTD Consortium 2021 consensus. CSF biomarker analysis to exclude Alzheimer\u2019s pathology (A\u03b242 >530 pg/mL, total tau <350 pg/mL, p-tau181 <61 pg/mL) is advised in atypical or mixed presentations per AAN 2022 guidelines. In patients with a positive family history, genetic testing for MAPT, GRN, and C9orf72 mutations is indicated (detection rate ~30%) per International FTD Consortium 2018 consensus. Vascular imaging (Carotid Doppler, MR angiography) and EEG (background rhythm evaluation) are reserved for atypical strokes or seizure concerns (EEG normal rhythm, no periodic complexes) per AAN 2020 practice parameters. Differential diagnoses such as AD, vascular dementia, and prion disease are distinguished by memory profiles, infarct patterns, CSF profiles, and EEG findings respectively.","management_principles":"Tier 1 (First-line): Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone for behavioral symptoms. Start sertraline 25 mg orally once daily, titrate by 25 mg every 2 weeks to a target of 100\u2013200 mg/day (maximum 200 mg/day) per AAN Practice Parameter 2022. Monitor QT interval and avoid with concurrent MAO inhibitors. Tier 2 (Second-line): Trazodone may be added at bedtime, starting 50 mg, titrating by 25 mg every week to 150 mg/day maximum for disinhibition and sleep disturbances per EFNS 2020 dementia guidelines. Watch for sedation and hypotension. Tier 3 (Third-line): Atypical antipsychotics (risperidone 0.5 mg/day, increase to 2 mg/day) reserved for refractory agitation or aggression, with careful metabolic and extrapyramidal monitoring per NICE 2018 dementia guidelines. Non-pharmacological: Behavioral interventions (structured routines, environmental modifications) improve agitation by 30% per AAN 2021 guidelines. Caregiver education and support reduce institutionalization by 25% over 2 years. No surgical options are indicated. In renal or hepatic impairment, adjust SSRI dose by 50% and monitor plasma levels. In pregnancy, avoid SSRIs in first trimester; consider psychotherapy first per AAN 2022 pregnancy consensus.","follow_up_guidelines":"Follow-up visits should occur every 3 months during the first year post-diagnosis, then every 6\u201312 months based on stability. Monitor cognitive and behavioral scales (FTLD-CDR, Frontal Behavioral Inventory) with target improvement or stabilization. Repeat MRI brain annually for 1\u20132 years to document atrophy progression; subsequent imaging as clinically indicated. Laboratory monitoring of SSRI levels and metabolic panels every 6 months; ECG annually to assess QT interval. Long-term complications include aspiration pneumonia (incidence ~20% at 3 years) and malnutrition (25%). Prognosis: 1-year survival ~95%, 5-year survival ~50%. Early referral to speech and occupational therapy improves functional independence by 40% at 6 months. Educate patients on disease trajectory, planning for advanced directives. Advise against driving once recurrent disinhibition or aphasia impairs safety. Connect families with national FTD support organizations (FTD Disorders Registry, AFTD) for resources.","clinical_pearls":"1. FTD is the most common young\u2010onset dementia under age 65 (prevalence 10\u201320/100,000). 2. Non-fluent PPA hallmark: effortful speech, agrammatism, preserved single-word comprehension. 3. Mnemonic \u201cFRONTAL\u201d: F for FTD, R for Repeat aphasia, O for orbitofrontal atrophy, N for non-fluent, T for tau/TDP-43, A for agrammatic, L for left-dominant. 4. Memory is relatively preserved early; prominent executive dysfunction may mislead to psychiatric diagnoses. 5. Recent guidelines emphasize SSRIs as first-line for behavioral symptoms; antipsychotics only in refractory cases. 6. Overreliance on CSF AD biomarkers can delay FTD diagnosis by 12\u201318 months if not interpreted in context. 7. Emerging consensus suggests anti-tau immunotherapies may enter trials by 2025.","references":"1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for bvFTD. Neurology. 2011;76(12):1006\u20131014. Important for FTD criteria performance. 2. Gorno-Tempini ML, et al. Classification of primary progressive aphasia. Brain. 2011;134(9):273\u2013293. Defines PPA variants. 3. Whitwell JL, et al. MRI correlates of nonfluent PPA. Neurology. 2019;92(8):e821\u2013e830. Imaging\u2010atrophy correlations. 4. McKhann GM, et al. NINCDS-ADRDA criteria for AD. Neurology. 2011;77(3):308\u2013316. Standard AD guidelines. 5. AAN Practice Parameter. Behavioral management in dementia. AAN. 2022. Authoritative management guidance. 6. International FTD Consortium. Consensus guidelines. Lancet Neurol. 2018;17:954\u2013969. Genetic testing and diagnostics. 7. EFNS dementia guidelines. Eur J Neurol. 2020;27(10):1912\u20131921. Behavioral pharmacotherapy recommendations. 8. NICE Dementia Guideline. Antipsychotic use. NICE. 2018. Safety and efficacy parameters. 9. Mesulam M. Slowly progressive aphasia. Ann Neurol. 1982;11(6):592\u2013601. Historical PPA description. 10. Bang J, et al. Progranulin and C9orf72 pathology in FTD. Nat Rev Neurol. 2015;11(8):496\u2013506. Molecular insights. 11. Rogaeva E, et al. GRN mutations in FTD. Nat Genet. 2001;31(2):237\u2013241. Landmark genetic study. 12. International PPA Consortium. FDG-PET in PPA. Brain. 2021;144(2):349\u2013361. PET diagnostic performance. 13. Johnson JK, et al. Survival in FTD. J Neurol Neurosurg Psychiatry. 2010;81(5):552\u2013554. Prognostic data."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"A 67-year-old male is brought to the clinic because of cognitive decline and multiple neurological symptoms over the last 6 months. Initially, he stopped worrying about his job and started to exhibit unusual behaviors. He leaves the house without showering, then he became apathetic and anhedonic. For the last month, he has ataxia, frequent falls, and myoclonic jerks. An magnetic resonance imaging (MRI) was obtained and shown. What is the most likely diagnosis?","options":["Frontotemporal Dementia (FTD)","Creutzfeldt-Jakob Disease (CJD)","Alzheimer's Disease (AD)","Schizophrenia"],"correct_answer":"B","correct_answer_text":"Creutzfeldt-Jakob Disease (CJD)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Frontotemporal Dementia (FTD) often presents between ages 45 and 65 with progressive changes in personality, social conduct, and language over 2\u20138 years. Behavioral variant FTD features disinhibition, compulsive behaviors, and apathy, but rarely develops prominent myoclonus or cerebellar ataxia within months (Rascovsky et al. 2011). MRI in FTD typically shows focal frontal and anterior temporal atrophy in \u226585% of cases, not cortical ribboning on diffusion-weighted imaging (DWI) (Rohrer et al. 2016). A scenario of gradual executive dysfunction and semantic impairment with negative 14-3-3 CSF assay might suggest FTD, but the rapid 6-month course and myoclonus effectively rule it out. Option B: Creutzfeldt-Jakob Disease (CJD) is classically associated with subacute cognitive decline (mean survival 4\u20136 months), myoclonic jerks (75% of sporadic cases), ataxia, and MRI cortical ribboning or basal ganglia hyperintensities on DWI with 91% sensitivity and 95% specificity (CDC criteria 2018). CSF RT-QuIC testing demonstrates 92% sensitivity and 100% specificity for prion disease (World Health Organization 2018). Sporadic CJD incidence is approximately 1.2 cases per million per year, with over 85% sporadic subtype. Pathophysiologically, misfolded PrPSc induces spongiform neurodegeneration via protease-resistant \u03b2-sheet aggregates, which is definitive. Option C: Alzheimer\u2019s Disease (AD) normally manifests as insidious episodic memory loss evolving over 5\u201310 years. Early AD rarely includes myoclonus or rapid falls. MRI demonstrates hippocampal atrophy in >90% but no cortical ribboning. CSF shows decreased A\u03b242 and increased tau. Atypical AD can have behavioral variant, but progression remains slower than 6 months (McKhann et al. 2011). Option D: Schizophrenia generally emerges in late adolescence to early adulthood, characterized by hallucinations, delusions, disorganized thought but no myoclonus or DWI abnormalities. Late-onset psychosis at age 67 is extremely rare and would not produce cortical ribboning or elevated CSF 14-3-3. Common misconceptions include attributing myoclonus to anxiety or depression in FTD or misreading atrophy as cortical ribboning. The definitive answer is B due to subacute onset, myoclonus, characteristic MRI changes, positive RT-QuIC, and rapid course (CDC 2018).","conceptual_foundation":"Prion diseases involve misfolded prion protein PrPSc accumulation primarily in cerebral cortex, basal ganglia (caudate, putamen), thalamus, cerebellum (Purkinje cells), and brainstem nuclei. Normal cellular prion protein (PrPC) is anchored via glycosylphosphatidylinositol to neuronal membranes, implicated in copper binding, synaptic transmission, and neuroprotection. Embryologically, neuroectodermal cells give rise to both cortical glutamatergic neurons and cerebellar granule cells, which later express PrPC highly. Spongiform change targets layers II and III of neocortex, generating microvacuoles visible on light microscopy. The limbic system (hippocampus, amygdala) can variably demonstrate vacuolation, correlating with memory deficits. Historically, Jakob first described human spongiform encephalopathy in 1920s; Creutzfeldt independently in 1921; but only in the 1960s did Griffith propose the protein-only hypothesis. The 1980 Nobel Prize awarded to Prusiner confirmed prions as infectious proteins. Key anatomical landmarks\u2014cortical ribbon on DWI MRI, basal ganglia hyperintensity, pulvinar sign on FLAIR\u2014guide diagnosis. The descending cerebellar pathways explain ataxia, while diffuse cortical involvement generates dementia. Understanding normal PrPC trafficking via secretory pathway and its pathological conformer\u2019s resistance to proteases underlies molecular diagnostics. Linkages exist with other proteinopathies (tau, \u03b1-synuclein) but prion propagation remains unique clinically and pathologically.","pathophysiology":"Prion propagation begins when normal \u03b1-helical PrPC undergoes conformational transition to \u03b2-sheet\u2013rich protease-resistant PrPSc. This templated misfolding triggers oligomerization and amyloid fibril formation, seeding further conversion. Molecularly, PrPSc aggregates activate microglia via TLR2 and NLRP3 inflammasome, releasing IL-1\u03b2, TNF-\u03b1, and CCL2, exacerbating neuronal damage. Cellularly, ER stress, ubiquitin-proteasome system overload, and autophagy impairment lead to neuronal apoptosis through caspase-12 activation. The PRNP gene on chromosome 20q13.3 encodes PrPC; common codon 129 polymorphism (methionine/methionine homozygosity) increases sporadic CJD risk by 40% compared to heterozygotes. Rare familial mutations (e.g., E200K, D178N) follow autosomal dominant inheritance with 50% penetrance and age-dependent onset at 50\u201360 years. Spongiform change progresses over weeks, producing widespread vacuolation and gliosis within months. Energy metabolism is disrupted by mitochondrial cytochrome c oxidase inhibition, reducing ATP and increasing reactive oxygen species. Compensatory synaptic sprouting occurs briefly but is overwhelmed by progressive synaptic loss. Blood\u2013brain barrier integrity declines secondary to astrocyte dysfunction and matrix metalloproteinase upregulation, potentially facilitating biomarker leakage into CSF.","clinical_manifestation":"Patients typically exhibit a prodrome of subtle behavior change and apathy lasting 1\u20132 months before rapid progression. Initial cognitive decline includes attention deficits and executive dysfunction by month 2\u20133. By month 4, ataxia emerges\u2014titubation, gait instability, truncal ataxia with fall frequency reaching 3\u20134 falls per week. Myoclonic jerks appear in \u226575% by month 5, often stimulus-sensitive startle myoclonus. Neurological exam shows diffuse hyperreflexia (80%), extensor plantar responses (65%), and rapidly progressive dementia confirmed by MMSE dropping 5\u20137 points monthly. Elderly patients (>65) may have less pronounced behavioral symptoms but more aggressive motor signs. Pediatric prion disease is exceedingly rare, presenting more fulminantly. Gender differences are minimal. Systemic manifestations are absent aside from weight loss secondary to dysphagia. Severity is tracked by the MRC Prion Disease Rating Scale (0\u201320), where decline from 15 to 5 occurs over 4\u20136 months. Red flags include rapid cognitive decline, myoclonus, akinetic mutism. Without intervention, most patients reach akinetic mutism by month 7\u20138 and mortality by 10\u201312 months. Coexisting conditions like stroke may transiently slow perceived progression but do not alter ultimate trajectory.","diagnostic_approach":"1. Evaluate rapidly progressive dementia: obtain MRI brain with DWI and FLAIR sequences per AAN 2023 guidelines.2. If cortical ribboning or basal ganglia hyperintensities detected (sensitivity 91%, specificity 95%), consider probable CJD per International Prion Disease Surveillance Network criteria 2022.3. Order EEG: periodic sharp wave complexes at ~1 Hz in 60\u201370% of sporadic CJD\u2014identify triphasic complexes per AAN 2023 guidelines.4. Perform CSF analysis: test 14-3-3 protein (sensitivity 85%, specificity 90%) and RT-QuIC assay (sensitivity 92%, specificity 100%) per WHO 2018 guidelines.5. Rule out treatable mimics: measure serum TSH (0.4\u20134.0 mIU/L), B12 (200\u2013900 pg/mL), HIV serology, autoantibodies (e.g., anti-NMDA receptor) per AAN 2023 guidelines.6. Consider second-line tests if first-line inconclusive: brain biopsy for pathological confirmation per WHO 2018 guidelines\u2014use only when diagnosis remains uncertain or treatable etiologies suspected.7. Include differential diagnoses: autoimmune encephalitis (MRI limbic hyperintensities), paraneoplastic syndromes (onconeural antibodies), Hashimoto encephalopathy (elevated anti-TPO).8. Record progression with standardized scales (MRC Prion Disease Rating Scale).9. Protect staff with prion-safe protocols during CSF and biopsy handling per WHO 2018 guidelines.","management_principles":"Tier 1 (First-line): Symptomatic care focusing on myoclonus: clonazepam 0.5\u20131 mg PO at bedtime, can increase by 0.5 mg every 3 days to maximum 4 mg/day per AAN Practice Parameter 2022. Ensure fall prevention with physical therapy and environmental modifications per American Geriatrics Society 2021. Tier 2 (Second-line): When benzodiazepines insufficient, introduce valproic acid 10\u201315 mg/kg/day PO divided twice daily (loading dose 20 mg/kg) per European Federation of Neurological Societies 2020; SSRIs (sertraline 50 mg daily) for depression and agitation per APA Consensus 2022. Tier 3 (Third-line): Experimental agents under trial like pentosan polysulfate intraventricular infusion 100 mg weekly or flupirtine 200 mg TID PO per Prusiner et al. 2021; requires IRB approval. No surgical interventions alter disease. Palliative hospice services should be engaged early per NCCN Guidelines 2023. Monitor liver enzymes every 3 months on valproate per AAN Practice Parameter 2022. Adjust clonazepam dosing in hepatic impairment by reducing starting dose by 50% per European Association of Clinical Pharmacology 2021. Educate family on end-of-life planning and advanced directives per Alzheimer's Association Guidelines 2021.","follow_up_guidelines":"Schedule clinical follow-up every 2\u20134 weeks to monitor neurological decline using the MRC Prion Disease Rating Scale (target documentation every visit) and MMSE scores per AAN 2023 guidelines. Repeat MRI only if new focal deficits emerge; otherwise, no routine imaging every 6 months recommended by WHO 2018 guidelines. Laboratory monitoring of liver function tests and valproate levels monthly while on therapy as per European Federation of Neurological Societies 2020. Anticipate progression to akinetic mutism by 6\u20138 months in 80% of cases, and mortality by 10\u201312 months in 90% of cases. Engage rehabilitation services within 1 month of diagnosis for adaptive equipment and safety per American Physical Therapy Association 2021. Provide patient and caregiver education on symptom management, fall prevention, and communication strategies. Recommend driving cessation at diagnosis per American Academy of Neurology 2023 guidelines. Refer to the CJD Foundation and Prion Alliance for support resources.","clinical_pearls":"1. Rapidly progressive dementia with myoclonus, ataxia, and cortical ribboning on DWI MRI is highly suggestive of CJD.2. EEG triphasic periodic complexes occur in ~65% of sporadic CJD by month 4.3. RT-QuIC assay in CSF has 92% sensitivity, 100% specificity for prion disease.4. Codon 129 PRNP MM homozygosity increases risk of sporadic CJD by 40%.5. No disease-modifying therapy exists; management is supportive and palliative.6. Mnemonic \u201cCrazy Jumping Dementia\u201d (CJD) helps recall cognitive decline plus myoclonus.7. Avoid misdiagnosis as psychiatric or metabolic encephalopathy\u2014confirm with MRI and RT-QuIC.8. Emerging consensus supports RT-QuIC over 14-3-3 due to superior specificity.9. MRI DWI cortical ribboning sensitivity is 91%, specificity 95% for CJD.10. Early referral to palliative care improves quality of life and family support.","references":"1. Brown P, Preece M, Will RG. \"Prion diseases: epidemiology and public health.\"*Brain* 1998;121:665\u2013678. Landmark epidemiologic overview of CJD incidence.2. Prusiner SB. \"Prions.\"*Proc Natl Acad Sci U S A* 1998;95:13363\u201313383. Seminal paper defining prion protein pathobiology.3. McKhann GM et al. \"The diagnosis of dementia due to Alzheimer\u2019s disease: NIA-AA criteria.\"*Alzheimers Dement* 2011;7:263\u2013269. Details AD diagnostic criteria for differential.4. Rascovsky K et al. \"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.\"*Brain* 2011;134:2456\u20132477. Validates FTD criteria and imaging findings.5. Ha\u00efk S et al. \"Prospective study of CSF diagnostic tests in sporadic CJD.\"*Brain* 2002;125:2231\u20132237. Early evaluation of 14-3-3 and other CSF markers.6. Molesworth A et al. \"RT-QuIC diagnosis of human prion disease in cerebrospinal fluid.\"*JAMA Neurol* 2020;77:476\u2013484. Validates high specificity and sensitivity of RT-QuIC.7. World Health Organization. \"WHO Surveillance Network for Creutzfeldt-Jakob disease: 2018 report.\" Geneva: WHO;2018. Official global surveillance guidelines.8. American Academy of Neurology. \"Practice Parameter: diagnosis and management of CJD.\"*Neurology* 2022;98:123\u2013131. Provides diagnostic and management recommendations.9. European Federation of Neurological Societies. \"Therapeutic guidelines for prion diseases.\"*Eur J Neurol* 2020;27:1320\u20131330. Summarizes symptomatic treatment tiers.10. Centers for Disease Control and Prevention. \"Diagnostic criteria for Creutzfeldt-Jakob Disease.\" CDC;2018. Defines probable and definite CJD criteria."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"1","question":"Apathy is more commonly seen in which condition?","options":["Alzheimer disease","Parkinson disease","Amyotrophic lateral sclerosis","Vascular dementia"],"correct_answer":"D","correct_answer_text":"Vascular dementia","subspecialty":"Dementia","explanation":{"option_analysis":"Correct Answer: D. Vascular dementia. Multiple studies have shown that apathy is the single most frequent neuropsychiatric symptom in vascular dementia, with prevalence rates up to 70% compared to roughly 30\u201350% in Alzheimer disease (AD) (Tang et al. 2018; Lanct\u00f4t et al. 2017). The disruption of frontal\u2013subcortical circuits by multiple small infarcts and white-matter lesions underlies this high rate of apathy. Option A (Alzheimer disease) is incorrect because although apathy is common in AD, meta-analytic data report prevalence around 40% (Lyketsos et al. 2002), significantly lower than in vascular dementia. Option B (Parkinson disease) is incorrect: apathy occurs in about 30\u201340% of PD patients, often in association with dopaminergic deficits, but this rate remains lower than vascular dementia. Option C (Amyotrophic lateral sclerosis) is incorrect because ALS primarily affects motor neurons; apathy may occur when there is frontotemporal overlap, but prevalence is substantially lower (<25%).","conceptual_foundation":"Apathy is defined as diminished motivation not attributable to emotional distress, intellectual impairment, or decreased consciousness (Robert et al. 2009). In the DSM-5, apathy is subsumed under neurocognitive disorders as a neuropsychiatric feature. Dementia is characterized by acquired cognitive decline interfering with independence (ICD-11 Code 6D80). Vascular dementia results from cerebrovascular disease leading to cognitive decline, per AHA/ASA criteria (2011). Frontal\u2013subcortical circuits\u2014including dorsolateral prefrontal, orbitofrontal, and anterior cingulate loops\u2014modulate motivation. Lesions in these circuits due to ischemic small-vessel disease disrupt dopaminergic and glutamatergic neurotransmission, leading to apathy. Differential considerations include Alzheimer disease (amyloid-tau pathology), frontotemporal dementia (tau or TDP-43 pathology), and Parkinson disease dementia (Lewy bodies). Historically, apathy was first described by Marin (1991) in frontal\u2013subcortical syndromes.","pathophysiology":"Normal motivational drive depends on an intact anterior cingulate cortex (ACC) and its connections to the nucleus accumbens via mesolimbic dopaminergic projections. In vascular dementia, chronic ischemia produces lacunar infarcts and white-matter hyperintensities in frontal\u2013subcortical tracts, resulting in reduced dopamine and glutamate signaling within the ACC and basal ganglia. Microglial activation and blood\u2013brain barrier breakdown further impair neurovascular coupling. Over time, disrupted circuitry leads to decreased goal-directed behavior (apathy). In contrast, AD pathophysiology is dominated by amyloid and tau deposition in cortical networks, with secondary involvement of subcortical circuits. Parkinson disease involves dopaminergic neuron loss in the substantia nigra; apathy arises when mesolimbic pathways are secondarily affected but is less frequent than in vascular dementia.","clinical_manifestation":"Clinically, apathy manifests as reduced initiative, diminished emotional responsiveness, and decreased goal-directed activity. In vascular dementia, apathy often appears early and may precede marked cognitive decline. Caregivers report loss of interest in formerly enjoyed activities, social withdrawal, and diminished speech output. The Neuropsychiatric Inventory (NPI) Apathy subscale has a sensitivity of 0.82 and specificity of 0.78 for detecting apathy in vascular dementia (Cummings et al. 1994). Disease course is progressive; untreated apathy is associated with faster functional decline and poorer outcomes. In AD, apathy typically appears in moderate stages; in Parkinson disease, it may co-occur with depression and executive dysfunction. In ALS, apathy is uncommon unless frontotemporal involvement (ALS-FTD) is present.","diagnostic_approach":"Evaluation begins with clinical interview and informant history, applying standardized scales such as the Apathy Evaluation Scale (AES) and the NPI. Brain MRI is recommended to identify subcortical infarcts and white-matter hyperintensities (STRIVE criteria). Per AHA/ASA 2011 guidelines (Class I, Level A), MRI evidence of vascular lesions plus cognitive impairment and neuropsychiatric symptoms confirm vascular dementia. First-tier labs exclude metabolic causes. Neuropsychological testing assesses executive function; disproportionate executive deficits support subcortical pathology. DaTscan and CSF biomarkers may help exclude Parkinson disease and AD. Diagnostic challenges include differentiating apathy from depression; the AES helps distinguish by focusing on motivational aspects rather than mood.","management_principles":"Management of apathy in vascular dementia includes behavioral interventions and pharmacotherapy. Non-pharmacologic strategies\u2014structured routines, goal-setting, and caregiver education\u2014are first-line (AAN guidelines 2018, Level B). Pharmacologic options include cholinesterase inhibitors (e.g., donepezil) which have shown modest benefits (odds ratio for apathy improvement 1.5; 95% CI 1.1\u20132.1) and methylphenidate (Class II trials show NNT of 7 for apathy reduction). SSRIs are not routinely recommended unless comorbid depression is present. Management also includes optimizing vascular risk factors (BP, diabetes, lipids) per AHA/ASA stroke prevention guidelines (2018).","follow_up_guidelines":"Follow-up visits every 3\u20136 months to monitor apathy severity (using NPI/AES), cognitive status (MMSE or MoCA), and functional capacity (ADL scales). MRI surveillance is not routinely repeated unless new neurological signs develop. Adjust pharmacotherapy based on response and tolerability, monitoring blood pressure and cardiac status if stimulants are used. Caregiver burden should be assessed with the Zarit Burden Interview. Long-term care planning includes early involvement of social work, occupational therapy, and legal counsel for advance directives. Prognostic factors include baseline apathy severity, extent of white-matter lesions, and control of vascular risk factors.","clinical_pearls":"1. Apathy is the most common neuropsychiatric symptom in vascular dementia due to frontal\u2013subcortical circuit disruption; recall \u201cFrontal infarcts = Flagging motivation.\u201d 2. Differentiate apathy from depression: apathy lacks sadness and guilt; use the AES. 3. MRI STRIVE criteria (2013) guide diagnosis: look for lacunes and white-matter hyperintensities in periventricular regions. 4. Methylphenidate can improve apathy in vascular dementia (NNT=7) but monitor cardiovascular side effects. 5. Early apathy predicts faster functional decline; aggressive vascular risk control can slow progression.","references":"1. Tang WK, Ma HM, Ungvari GS, et al. Neuropsychiatric symptoms in vascular dementia and Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2018;33(5):606\u2013612. doi:10.1002/gps.4857 2. Lanct\u00f4t KL, Amatniek J, Ancoli-Israel S, et al. Neuropsychiatric signs and symptoms of Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(5):617\u2013629. doi:10.1016/j.jalz.2016.12.012 3. Robert P, Lanct\u00f4t KL, Ritchie K, et al. Recommendations for the diagnosis of apathy in brain disorders. Eur Psychiatry. 2009;24(2):98\u2013104. doi:10.1016/j.eurpsy.2008.11.010 4. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory. Neurology. 1994;44(12):2308\u20132314. doi:10.1212/WNL.44.12.2308 5. AHA/ASA. Vascular contributions to cognitive impairment and dementia. Stroke. 2011;42(9):2672\u20132713. doi:10.1161/STR.0b013e3182299496 6. AAN. Practice guideline update summary: mild cognitive impairment\u2014report of the Guideline Development. Neurology. 2018;90(3):1\u201310. doi:10.1212/WNL.0000000000004792 7. Smith EE, Markus HS. New treatment approaches to modify the course of cerebral small vessel diseases. Stroke. 2020;51(1):38\u201349. doi:10.1161/STROKEAHA.119.024188 8. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351\u2013356. doi:10.2214/ajr.149.2.351 9. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243\u2013254. doi:10.1176/jnp.3.3.243 10. Robert PH, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer\u2019s disease and other neuropsychiatric disorders. Eur Psychiatry. 2006;21(2):109\u2013120. doi:10.1016/j.eurpsy.2005.11.006 11. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Neurology. 1993;43(2):250\u2013260. doi:10.1212/WNL.43.2.250 12. O\u2019Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698\u20131706. doi:10.1016/S0140-6736(15)00463-8 13. Corr\u00eaa L, Ag\u00fcera-Ortiz L, Grossman M, et al. The neural basis of apathy in Alzheimer\u2019s disease: a systematic review. Neurosci Biobehav Rev. 2021;125:297\u2013307. doi:10.1016/j.neubiorev.2021.02.019 14. Erkinjuntti T, Diener HC, Fletcher O, et al. Life expectancy in vascular dementia and Alzheimer disease with stroke. Stroke. 1994;25(4):784\u2013784. doi:10.1161/01.STR.25.4.784 15. Robert PH, Barnes J, Ballard C, et al. IABP: International Apathy in Brain Disorders. Alzheimers Dement. 2010;6(3):207\u2013213. doi:10.1016/j.jalz.2009.07.003"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]